Literature DB >> 2373132

The pharmacokinetics of d-sotalol and d,l-sotalol in healthy volunteers.

J M Poirier1, P Jaillon, B Lecocq, V Lecocq, A Ferry, G Cheymol.   

Abstract

The pharmacokinetics of d-sotalol has been studied in six healthy volunteers given single doses of 0.25, 0.50, 1, 2 mg.kg-1 i.v. and one 100 mg oral dose in comparison with the kinetics of 1 mg.kg-1 i.v. of dl-sotalol. There was no significant difference in the disposition of the d-enantiomer and the racemate. The terminal half-life averaged 7.2 h, and the kinetics was linear, with a mean total clearance of 0.13 l.h-1.kg-1. Renal clearance of d-sotalol represented 56 to 77% of total clearance. The absolute systemic availability of oral d-sotalol was close to 100% and the elimination half-life of the oral-d-enantiomer was similar to that of the i.v. form (7.5 h).

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2373132     DOI: 10.1007/bf00278585

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  24 in total

1.  Cardiovascular pharmacology of two new beta-adrenergic receptor antagonists.

Authors:  H C Stanton; T Kirchgessner; K Parmenter
Journal:  J Pharmacol Exp Ther       Date:  1965-08       Impact factor: 4.030

2.  Electrophysiologial and beta-receptor blocking effects of MJ 1999 on dog and rabbit cardiac tissue.

Authors:  H C Strauss; J T Bigger; B F Hoffman
Journal:  Circ Res       Date:  1970-06       Impact factor: 17.367

3.  Antiarrhythmic activity of the dextro- and levorotatory isomers of 4-(2-isopropylamino-1-hydroxyethyl) methanesulfonanilide (MJ 1999).

Authors:  P Somani; D L Watson
Journal:  J Pharmacol Exp Ther       Date:  1968-12       Impact factor: 4.030

4.  Sotalol-induced delayed ventricular repolarization in man.

Authors:  N Edvardsson; I Hirsch; H Emanuelsson; J Pontén; S B Olsson
Journal:  Eur Heart J       Date:  1980-10       Impact factor: 29.983

5.  Antiarrhythmic and antifibrillatory actions of the levo- and dextrorotatory isomers of sotalol.

Authors:  J J Lynch; D J Wilber; D G Montgomery; T M Hsieh; E Patterson; B R Lucchesi
Journal:  J Cardiovasc Pharmacol       Date:  1984 Nov-Dec       Impact factor: 3.105

6.  Acute prolongation of myocardial refractoriness by sotalol.

Authors:  D H Bennett
Journal:  Br Heart J       Date:  1982-06

7.  Sotalol prolongation of the QTc interval in hypertensive patients.

Authors:  P J Neuvonen; E Elonen; A Tanskanen; J Tuomilehto
Journal:  Clin Pharmacol Ther       Date:  1982-07       Impact factor: 6.875

8.  Stereoselective clearance and distribution of intravenous propranolol.

Authors:  L S Olanoff; T Walle; U K Walle; T D Cowart; T E Gaffney
Journal:  Clin Pharmacol Ther       Date:  1984-06       Impact factor: 6.875

9.  Quantitative liquid chromatographic determination of sotalol in human plasma.

Authors:  J M Poirier; P Jaillon; G Cheymol
Journal:  Ther Drug Monit       Date:  1986       Impact factor: 3.681

10.  The acute cardiac electrophysiological effects of intravenous sotalol hydrochloride.

Authors:  D E Ward; A J Camm; R A Spurrell
Journal:  Clin Cardiol       Date:  1979-06       Impact factor: 2.882

View more
  10 in total

Review 1.  Therapeutic drug monitoring: antiarrhythmic drugs.

Authors:  T J Campbell; K M Williams
Journal:  Br J Clin Pharmacol       Date:  1998-10       Impact factor: 4.335

2.  Physiologically based pharmacokinetic models in the prediction of oral drug exposure over the entire pediatric age range-sotalol as a model drug.

Authors:  Feras Khalil; Stephanie Läer
Journal:  AAPS J       Date:  2014-01-08       Impact factor: 4.009

3.  Interaction of class III antiarrhythmic drugs with muscarinic M2 and M3 receptors: radioligand binding and functional studies.

Authors:  H Uemura; Y Hara; M Endou; K Mori; H Nakaya
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-12       Impact factor: 3.000

4.  Stereospecific high-performance liquid chromatographic assay of sotalol in plasma.

Authors:  R A Carr; R T Foster; N H Bhanji
Journal:  Pharm Res       Date:  1991-09       Impact factor: 4.200

5.  Using Physiologically Based Pharmacokinetic (PBPK) Modelling to Gain Insights into the Effect of Physiological Factors on Oral Absorption in Paediatric Populations.

Authors:  Angela Villiger; Cordula Stillhart; Neil Parrott; Martin Kuentz
Journal:  AAPS J       Date:  2016-04-08       Impact factor: 4.009

Review 6.  Sotalol. An updated review of its pharmacological properties and therapeutic use in cardiac arrhythmias.

Authors:  A Fitton; E M Sorkin
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

7.  Adverse effects of a single dose of (+)-sotalol in patients with mild stable asthma.

Authors:  G Devereux; K Fishwick; T C Aiken; S J Bourke; D J Hendrick
Journal:  Br J Clin Pharmacol       Date:  1998-07       Impact factor: 4.335

8.  Stereoselective disposition of (+/-)-sotalol at steady-state conditions.

Authors:  C Fiset; F Philippon; M Gilbert; J Turgeon
Journal:  Br J Clin Pharmacol       Date:  1993-07       Impact factor: 4.335

Review 9.  Pharmacodynamic, pharmacokinetic and antiarrhythmic properties of d-sotalol, the dextro-isomer of sotalol.

Authors:  S V Advani; B N Singh
Journal:  Drugs       Date:  1995-05       Impact factor: 9.546

10.  Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup.

Authors:  Josée Bouchard; Greene Shepherd; Robert S Hoffman; Sophie Gosselin; Darren M Roberts; Yi Li; Thomas D Nolin; Valéry Lavergne; Marc Ghannoum
Journal:  Crit Care       Date:  2021-06-10       Impact factor: 9.097

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.